References

1. 1.
   CHUNG S C，GEDEBORG R，NICHOLAS O，et al. Acute myocardial infarction：A comparison of short-term survival in national outcome registries in Sweden and the UK［J］.Lancet，2014，383（9925）：1305-1312.
2. 2.
   The Writing Committee of the Report on Cardiovascular Health and Diseases in China.Key points interpretation of China Cardiovascular Health and Disease Report 2021［J］.Chin J Cardiovascular Med，2022，27（4）：305.
3. 3.
   MENG X M，YUAN J H，ZHOU Z F，et al. Evaluation of time-dependent phenotypes of myocardial ischemia-reperfusion in mice［J］.Aging（Albany NY），2023，15（19）：10627-10639.
4. 4.
   HU C C，WEI X，LIU J M，et al.Cardiac-targeted PIASy gene silencing mediates deSUMOylation of caveolin-3 and prevents ischemia/reperfusion-induced Na_v1.5 downregulation and ventricular arrhythmias［J］.Mil Med Res，2022，9（1）：58.
5. 5.
   LAN Z，TUO P，GAO Y G，et al. Research progress in treatment of acute myocardial infarction with traditional Chinese medicine［J］.J Snake，2023，35（2）：259-261，279.
6. 6.
   LIU Z M，LIU R X，et al.Understanding and experience of syndrome differentiation and treatment of coronary heart disease［J］.Acta Med Sin，1994，9（3）：46-49.
7. 7.
   DENG C X，HE D Y，SUN W，et al.Clinical observation of Danlou Tongbi decoction in treating angina pectoris of coronary heart disease with phlegm-stasis obstructing collaterals syndrome［J］.J Emerg Syndromes Tradit Chin Med，2023，32（1）：104-107.
8. 8.
   WU Y L.Theory of meridian diseases in traditional Chinese medicine and three-dimensional network system［J］.J Tradit Chin Med，2003，44（6）：407-409.
9. 9.
   CHANG C C.Theory and experimental research on prevention and treatment of cardiac sub-meridian-microvessel lesions guided by the theory of communication and bio-transformation through meridians in the theory of meridian and collateral［D］.Nanjing：Nanjing University of Chinese Medicine，2017.
10. 10.
    ZHAO L，LI L，WEI H F，et al.Evolvement of learning and memory ability in hyperlipedemic rats with phlegm and blood stasis syndromes［J］.Chin J Integr Med Cardio/Cerebrovasc Dis，2008，6（4）：415-417.
11. 11.
    YUAN Y，GAO Y X，ZHANG Q Y，et al.Construction and evaluation of a cerebral infarction Qi-Yin deficiency syndrome mouse model based on metabolomics［J］.Chin J Exp Tradit Med Form，2025，doi：.
12. 12.
    SHI Y L，GAO Y X，ZHANG Q Y，et al.Establishment and evaluation of a rat model with acute myocardial infarction in coronary heart disease and Qi-Yin deficiency syndrome induced by sleep deprivation combined with coronary artery ligation［J］.Chin J Exp Tradit Med Form，2025，doi：.
13. 13.
    LI G H，LUO B，LV Y X，et al.Dual effects of VEGF-B on activating cardiomyocytes and cardiac stem cells to protect the heart against short- and long-term ischemia-reperfusion injury［J］.J Transl Med，2016，14（1）：116.
14. 14.
    CHEN J，YE C，HU X，et al.Serum metabolomics model and its metabolic characteristics in patients with different syndromes of dyslipidemia based on nuclear magnetic resonance［J］.J Pharm Biomed Anal，2019，167：100-113.
15. 15.
    SUN J Z，NIU X Y，HAN L H，et al.Experimental study on micro-syndrome differentiation indicators of phlegm-turbidity syndrome［J］.Henan Tradit Chin Med，1996，21（2）：21-22.
16. 16.
    LI D，LI J，LIU Y，et al.Discussion on the modern biological basis of phlegm syndrome based on the basic theory of traditional Chinese medicine［J］.Liaoning J Tradit Chin Med，2020，47（2）：93-95.
17. 17.
    FENG J，YAN K P，ZHU M J，et al.Meta-analysis of the therapeutic effect of Gualou Xiebai Banxia Tang combined with Xuefu Zhuyu Tang on coronary heart disease angina pectoris from the perspective of phlegm and blood stasis［J］.Shaanxi J Tradit Chin Med，2021，42（3）：393-397.
18. 18.
    ZHANG Y K，HAN J B，WANG Q G，et al.Effect of Huatan Kaibi decoction on pre-thrombotic state and platelet aggregation rate in patients with coronary heart disease angina pectoris of phlegm-turbidity obstruction type［J］.Chin J Integr Med Cardio，2022，20（10）：1732-1735.
19. 19.
    BUTLER M J，CHAN W，TAYLOR A J，et al.Management of the no-reflow phenomenon［J］.Pharmacol Ther，2011，132（1）：72-85.
20. 20.
    CHEN C，WU D，LV X L，et al.Effect of electroacupuncture preconditioning on adhesion molecules and endothelial cell function in rats with no-reflow after acute myocardial infarction reperfusion［J］.Mod J Integr Tradit Chin West Med，2019，28（19）：2067-2071.
21. 21.
    LI F Z.Correlation analysis of traditional Chinese medicine syndromes and objective indicators in different clinical types of coronary heart disease［D］.Shenyang：Liaoning University of Traditional Chinese Medicine，2023.
22. 22.
    MA C L，WANG Y G，ZHENG G.Overview of methods for establishing animal models of coronary heart disease with phlegm-stasis intermingled syndrome［J］.Intern Med J Pract Tradit Chin Med，2015，29（11）：179-181.
23. 23.
    LI L，WANG A A，LIU Z X，et al.Research status and prospects of animal models of coronary heart disease with phlegm-stasis intermingled syndrome［J］.Chin J Tradit Chin Med，2023，38（3）：969-973.
24. 24.
    REN J G，LIU J X，WEI J H.Disease-syndrome combined pharmacology：Strategy and method for the study of traditional Chinese medicine pharmacology［J］.Chin J Tradit Chin Med，2021，46（19）：4922-4929.
25. 25.
    LI X Z.Pathological mechanism and foundation of formula-syndrome correspondence in a coronary heart disease model with phlegm-stasis intermingled syndrome［D］.Beijing：China Academy of Chinese Medical Sciences，2008.
26. 26.
    HE K，YAN L，LIN S Q，et al.Implication of IGF1R signaling in the protective effect of Astragaloside Ⅳ on ischemia and reperfusion-induced cardiac microvascular endothelial hyperpermeability［J］.Phytomedicine，2022，100：154045.
27. 27.
    LIU Z，HAN X，YOU Y，et al.Shuangshen ningxin formula attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial function［J］.J Ethnopharmacol，2024，323：117690.
28. 28.
    QIAN F.Study on the pathogenesis of phlegm-stasis obstructing collaterals syndrome in angina pectoris of coronary heart disease［J］.J Jilin Tradit Chin Med，2008，28（4）：241.
29. 29.
    ZHAO X D，SHI J X.Mechanism and therapies of cerebralvasospasm following subarachnoid hemorrhage［J］.J Med Postgraduates，2010，23（2）：218-222.
30. 30.
    LIU H，WANG H T.The changes of endothelin—A receptor mRNA in the cerebral basilartery of rats with subarachnoid hemorrhage［J］.Shaanxi Med J，2009，38（4）：402-404.
31. 31.
    WÖLKART G，STESSER H，SAA D Z，et al.Cardioprotective effects of atrasentan，an endothelin-A receptor antagonist，but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase［J］.Br J Pharmacol，2006，148（5）：671-681.
32. 32.
    LIU W W，LIU M L.Research progress on the prevention of cardiovascular diseases by ω-3 polyunsaturated fatty acids［J］.Chin J Cardiovasc Med，2018，23（6）：510-514.
33. 33.
    YUAN Q，XIE F，HUANG W，et al.The review of alpha-linolenic acid：Sources，metabolism，and pharmacology［J］.Phytother Res，2022，36（1）：164-188.
34. 34.
    LAI J S，CHEN C.The roles of cytochrome P450 metabolites of arachidonic acid in the regulation of vascular function［J］.Acta Physiol Sin，2021，73（4）：631-645.
35. 35.
    CHEN Q H.Relationship between arachidonic acid and atherosclerosis and thrombosis formation［J］.Prog Physiol Sci，1983，27（2）：112-117.
36. 36.
    HU Y，LI W，CHENG X，et al.Emerging roles and therapeutic applications of arachidonic acid pathways in cardiometabolic diseases［J］.Circ Res，2024，135（1）：222-260.